COMPANY CONFIDENTIAL. DO NOT DISCLOSE.
BioNTech is a German biotechnology company known for co-developing the first approved mRNA COVID-19 vaccine with Pfizer, as well as its focus on developing vaccines for cancer and infectious diseases. Though once a JMP customer, BioNTech decided not to renew one year, but later re-engaged after a period of inactivity to expand their license count thanks to internal advocacy and strategic outreach. Congratulations, DACH Team 1, on this sales win!
Key takeaways:
-
Understanding BioNTech’s software needs was crucial. BioNTech needed a tool for its complex clinical trials to help with optimizing experiments, drug formulation manufacturing, reducing variability, improving robustness of its processes, and more. Prior to using JMP, BioNTech “did a lot of stuff in Excel and now they have a tool where they can get results much faster and much more efficiently,” Jessica Bechtel says.
-
Through strategic JMP customers and meaningful outreach like hosting JMP Inspire sessions, Jessica’s team was able to gain an additional 19 JMP licenses, gaining visibility across departments despite BioNTech’s internal organizational issues.
-
Jessica advises focusing on organizations within JMP’s strategic industries that need to get fast and efficient innovation done. If a company is racing to innovate, like BioNTech with their vaccine development, they will benefit from an advanced data analysis tool like JMP.
Integral players:
